Spironolactone Tablet, Coated
Product Images NDC 82804-975

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 82804-975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-977-30 (100mg)

Spironolactone 100 mg coated tablets packaging label from Proficient Rx LP. The label indicates a bottle containing 30 tablets, each round, white to off-white, scored, convex, and debossed with "854" on one side and "O" on the other. Manufactured by Oxford Pharmaceuticals in Birmingham, Alabama, with storage instructions at 20°-25°C (68°-77°F).*

FDA Label Image

82804-975-30 (25mg)

Label for Spironolactone 25 mg coated tablets, prescription strength, with a package count of 30 tablets. The label shows the product is packaged by Proficient Rx LP and manufactured by Oxford Pharmaceuticals, LLC in Birmingham, Alabama. Tablets are described as round, white to off-white, convex, coated, with '852' debossed on one side and 'O' on the other. Storage instructions specify 20°-25°C (68°-77°F).*

FDA Label Image

82804-976-30 (50mg)

Label for Spironolactone 50 mg coated tablets by Proficient Rx LP. The label states the package contains 30 tablets, each with 50 mg of Spironolactone USP. Tablets are oval, white to off-white, scored, convex, coated, with '853' debossed on one side and 'O' on the other. Manufactured by Oxford Pharmaceuticals, LLC in Birmingham, Alabama.*

FDA Label Image

Figure 1 (Figure1)

A survival probability line chart comparing Spironolactone and placebo groups over months. The x-axis represents time in months up to 48, and the y-axis shows survival probability from 0.0 to 1.0. The chart indicates higher survival probability for Spironolactone than placebo, with statistical significance (log-rank p < 0.001).*

FDA Label Image

Figure 2 (Figure2)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups in a clinical study comparing Spironolactone to placebo. Subgroups are stratified by age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The horizontal axis ranges from 0.2 to 1.4, indicating comparative effectiveness between Spironolactone and placebo.*

FDA Label Image

20 (Spironolactone Tablets Usp 1)

Chemical structure of spironolactone showing its molecular framework including lactone and thioacetate groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.